Literature DB >> 12034382

Short-course preoperative radiation therapy for operable rectal cancer.

Keith Tankel1, John Hay, Roy Ma, Elizabeth Toy, Stephan Larsson, John MacFarlane.   

Abstract

BACKGROUND: Short course neoadjuvant radiation has been shown to provide improved local control of rectal cancer in a clinical trial population even in the presence of standardized surgical techniques. However, this use of hypofractionated radiotherapy has been limited in North America owing to concerns over toxicity.
METHODS: Patients considered to have locally advanced rectal carcinoma received a radiation dose of 25 Gy given in five fractions to the posterior pelvis. Definitive surgery was then performed within 2 weeks. Retrospective analysis was performed.
RESULTS: Sixty-three patients, of whom 60 were assessable, were treated with preoperative short course radiotherapy at the British Columbia Cancer Agency between 1991 and 1998, and 97% proceeded to R0 resection. Local recurrence developed in 3 patients (5%). Five-year actuarial overall and relapse-free survival rates for the group were 71% and 69%, respectively. The actuarial rates of relapse-free survival by stage at 5 years were stage 1 83%, stage II 75%, stage III 62%, and stage 4 0%. Eleven patients (18%) experienced a postoperative complication.
CONCLUSION: Short course preoperative radiotherapy for operable rectal cancer can be delivered to a general population and produce high pelvic control rates with acceptable toxicity.

Entities:  

Mesh:

Year:  2002        PMID: 12034382     DOI: 10.1016/s0002-9610(02)00832-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Feasibility of adequate resectable rectal cancer treatment in a third-level hospital.

Authors:  J Gallego-Plazas; F Menárguez-Pina; A Maestre-Peiró; V González-Orozco; F Andreu; M J Escudero-Barea; M A Morcillo
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

2.  Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.

Authors:  Kjersti Flatmark; Ragnhild V Nome; Sigurd Folkvord; Ase Bratland; Heidi Rasmussen; Mali Strand Ellefsen; Øystein Fodstad; Anne Hansen Ree
Journal:  Radiat Oncol       Date:  2006-08-03       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.